Figure 2
Immunoreactivity of glia is unchanged in APP swe / PS1 Δ E9 mice following administration of bexarotene. (A) IBA1 levels in 11 month old male and female APP swe /PS1 Δ E9 mice are unaffected by bexarotene treatment in both cortex [F(1,27)=2.231, p=0.147] and hippocampus [F(1,27)=2.127, p=0.156], and no significant effect of gender was detected [F(1,27)=0.665, p=0.422]. No significant interactions were detected. Error bars represent standard deviation. N-values: non-transgenics (veh), males=5, females=5; APP swe /PS1Δ E9, males: Bex =8, Veh=7, females: Bex=5, Veh=3. Representative images of IBA1 staining and microglial morphology in (B) F tg Veh, (C) F tg Bex, (D) M Tg Veh and (E) M Tg Bex. Scale bars = 500 um large images and 50 um on inserts. Morphology shows an amoeboid (active) state with clusters of activated microglia in APP swe /PS1 Δ E9 animals (B,D). This morphology and clustering appears unchanged by treatment with bexarotene (C,E).